1361223-23-5

Upstream product

• 106-37-6 1.4-dibromobenzene 
• 1361215-54-4 1,1,1-trifluoro-2-(4-((2R)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 122243-28-1 2‐(4‐bromophenyl)‐1,1,1‐trifluoropropan‐2‐ol 
• 1361215-53-3 2-(4-((2R)-2-((benzyloxy)methyl)-4-(thiophen-2-ylsulfonyl)-1-piperazinyl)phenyl)-1,1,1-trifluoro-2-propanol 
• 1361215-52-2 (3R)-3-((benzyloxy)methyl)-1-(2-thiophenylsulfonyl)piperazine 
• 1255208-74-2 (3S)-3-((benzyloxy)methyl)-2,5-piperazinedione 
• 2516-34-9 cyclobutylamine 
• 1361215-49-7 ((2R)-4-(2-thiophenylsulfonyl)-1-(4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)-phenyl)-2-piperazinyl)methyl methanesulfonate 

Relevant academic research and scientific papers

SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.